AZATHIOPRINE INDUCED PANCYTOPENIA-A CASE REPORT
DOI:
https://doi.org/10.22159/ijpps.2017v9i2.15801Keywords:
Azathioprine, Pancytopenia, Thiopurine methyltransferaseAbstract
Azathioprine (AZA), a prodrug of 6 mercaptopurine, is an immunosuppressant that can be used as adjunctive therapy with corticosteroids in the treatment of arteritic form of ischemic optic neuropathy. Although myelotoxicity is known to occur while using azathioprine, severe pancytopenia is rarely seen. Patients with thiopurine methyltransferase (TPMT) deficiency are at high risk of developing severe myelosuppression. A 63 year* old female with ischemic optic neuropathy was initiated treatment with oral methylprednisone. As two courses of oral steroids showed no significant improvement, oral azathioprine 25 mg twice daily was added and gradually increased to 50 mg twice daily with relief of symptoms. 6 mo later, she was admitted with acute stroke and lab reports showed low levels of total blood counts or pancytopenia. The patient was put on broad spectrum antibiotics; given injection of granulocyte colony stimulating factor 300 mcg subcutaneously and blood transfusion as correction till counts normalised. She improved over 14 d and on next follow-up counts were in normal range. Causality was assessed by Naranjo causality assessment scale and a probable relationship was obtained between azathioprine and pancytopenia with a score of 6. Variations in TPMT activity occurs due to genetic polymorphism. Physicians should be aware of the possibility of myelosuppression while prescribing azathioprine. Frequent blood count monitoring is the most convenient way to avoid this problem where testing for TPMT deficiency is not possible.
Downloads
References
Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 2006;55:369-89.
Hadda V, Pandey BD, Gupta R. Azathioprine-induced pancytopenia. A serious complication. J Postgrad Med 2009; 55:139-40.
Fraser JA, Weyand CM, Newman NJ, Biousse V. The treatment of giant cell arteritis. Rev Neurol Dis 2008;5:140-52.
De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136-8.
Solanki A, Choksi K, Patel S. Review article on treatment of pemphigus vulgaris. Int J Curr Pharm Res 2012;4:10-4.
Bisht R, Sharma D. Sjogren’s disease: a comprehensive review in recent clinical and experimental findings in pathogenesis and pharmacotherapy. Asian J Pharm Clin Res 2011;4:32-9.
De Boer NK, Mulder CJ, Van Bodegravon AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 2005;63:444-6.
Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783-800.
Murugesan R, Vahab SA, Patra S, Rao R, Rao J, Rai P, et al. Thiopurine S-methyltransferase alleles, TPMT (*)2, (*)3B and (*)3C, and genotype frequencies in an Indian population. Exp Ther Med 2010;1:121-7.
Colombel JF, Ferrari N, Debuysree H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with chron’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
Seddik M, Texier F, Ferrari N, Cortot A, Libersa C, Broly F, et al. Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease. Gastroenterology 2003;124:A192-3.
Bradford K, Shih DQ. Optimising 6 mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011;17:4166-73.
